Home of Fast Facts and Fast Fact CME - Palliative Care ...



FAST FACTS AND CONCEPTS #393CAR-T CELL IMMUNOTHERAPY: WHAT YOU NEED TO KNOWRamy Sedhom MD, Arjun Gupta MD, Areej El-Jawahri MDBackground: Immunotherapy using one’s own T-cells that are genetically engineered to express a chimeric antigen receptor (CAR) is an emerging therapy for hematologic and non-hematologic cancer. CAR-T cell therapy has induced rapid and durable clinical responses in otherwise fatal cancers, but is associated with unique, possibly severe, toxicities. This Fast Fact will discuss the basics of CAR-T cell therapy for clinicians, approved indications, and toxicities. CAR-T Cell Therapy: CAR T-cell therapy alters the function of a patient’s own T cells or those of a healthy donor, to recognize and kill cancer cells ADDIN EN.CITE <EndNote><Cite><Author>Brudno</Author><Year>2018</Year><RecNum>5683</RecNum><DisplayText>(1)</DisplayText><record><rec-number>5683</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1574802158" guid="849b9b81-5e8b-4873-a751-471b9c81ba4c">5683</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Brudno, J. N.</author><author>Kochenderfer, J. N.</author></authors></contributors><auth-address>Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH Building 10 room 3-3330, Bethesda, Maryland 20892, USA.</auth-address><titles><title>Chimeric antigen receptor T-cell therapies for lymphoma</title><secondary-title>Nat Rev Clin Oncol</secondary-title></titles><periodical><full-title>Nat Rev Clin Oncol</full-title></periodical><pages>31-46</pages><volume>15</volume><number>1</number><edition>2017/09/01</edition><keywords><keyword>Antigens, CD19/*immunology</keyword><keyword>Humans</keyword><keyword>Immunotherapy, Adoptive/*methods</keyword><keyword>Ki-1 Antigen/immunology</keyword><keyword>Lymphoma/*therapy</keyword><keyword>Receptors, Antigen, T-Cell/*immunology/therapeutic use</keyword></keywords><dates><year>2018</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1759-4782 (Electronic)&#xD;1759-4774 (Linking)</isbn><accession-num>28857075</accession-num><urls><related-urls><url>;(1). These tumor-targeted T cells are engineered in the laboratory, expanded to large numbers and infused back into the patient a few weeks after harvest. Once infused, the CAR-T cells divide and multiply, bypassing the barriers and incremental kinetics of active immunization, exerting both immediate and long-term anti-tumor effects. Patients who receive CAR T-cell therapy have a recovery/monitoring period of approximately 3-6 months. During this period, patients are evaluated for side effects and treatment response. Care is usually limited to specialty referral centers. While CAR T-cell therapy is being studied widely in solid tumors, such as prostate, breast, lung and colorectal cancer, the following are FDA-approved indications for CAR T-cell therapy:Tisagenlecleucel - children or adults 25 or younger with relapsed or refractory acute lymphoblastic leukemia.Axicabtageneciloleucel - Relapsed/Refractory large B-cell lymphoma despite ≥ 2 systemic therapies.CAR T-cells in the treatment of multiple myeloma were granted fast track designation by the FDA. Response Rates and Durable Remissions: Compared to historical controls, objective and complete response rates have been impressive in patients who have progressed on other treatments. Of 24 patients enrolled in a single institution trial of tisagenlecleucel, 46% of patients in the diffuse large b-cell cohort had a complete remission, while 71% of patients in the follicular lymphoma cohort had a complete response. These remissions were durable, with 60% of patients being relapse-free at 4 years ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1" ExcludeYear="1"><RecNum>5692</RecNum><DisplayText>(2)</DisplayText><record><rec-number>5692</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1574803341" guid="2afc8628-211d-4a8f-900d-a790f30e120c">5692</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Chong EA, Svoboda J, Nasta SD, et al. CD19‐directed car t cell therapy (CTL019) for relapsed/refractory diffuse large B‐cell and follicular lymphomas: four year outcomes. Hematol Oncol. 2019;37(suppl S2):137-138. doi: 10.1002/hon.96_2629.</title></titles><dates></dates><urls></urls></record></Cite></EndNote>(2). For comparative purposes, prognosis in this cohort of patients is poor, with a median overall survival of 4.4 months and 1 year overall survival rate of 23%PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYW4gZGVuIE5lc3RlPC9BdXRob3I+PFllYXI+MjAxNjwv

WWVhcj48UmVjTnVtPjU3NTY8L1JlY051bT48RGlzcGxheVRleHQ+KDMpPC9EaXNwbGF5VGV4dD48

cmVjb3JkPjxyZWMtbnVtYmVyPjU3NTY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFw

cD0iRU4iIGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVz

dGFtcD0iMTU3NzEyOTYyMCI+NTc1Njwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1l

PSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh

dXRob3I+VmFuIGRlbiBOZXN0ZSwgRS48L2F1dGhvcj48YXV0aG9yPlNjaG1pdHosIE4uPC9hdXRo

b3I+PGF1dGhvcj5Nb3VuaWVyLCBOLjwvYXV0aG9yPjxhdXRob3I+R2lsbCwgRC48L2F1dGhvcj48

YXV0aG9yPkxpbmNoLCBELjwvYXV0aG9yPjxhdXRob3I+VHJuZW55LCBNLjwvYXV0aG9yPjxhdXRo

b3I+TWlscGllZCwgTi48L2F1dGhvcj48YXV0aG9yPlJhZGZvcmQsIEouPC9hdXRob3I+PGF1dGhv

cj5LZXR0ZXJlciwgTi48L2F1dGhvcj48YXV0aG9yPlNocGlsYmVyZywgTy48L2F1dGhvcj48YXV0

aG9yPkR1aHJzZW4sIFUuPC9hdXRob3I+PGF1dGhvcj5NYSwgRC48L2F1dGhvcj48YXV0aG9yPkJy

aWVyZSwgSi48L2F1dGhvcj48YXV0aG9yPlRoaWVibGVtb250LCBDLjwvYXV0aG9yPjxhdXRob3I+

U2FsbGVzLCBHLjwvYXV0aG9yPjxhdXRob3I+TW9za293aXR6LCBDLiBILjwvYXV0aG9yPjxhdXRo

b3I+R2xhc3MsIEIuPC9hdXRob3I+PGF1dGhvcj5HaXNzZWxicmVjaHQsIEMuPC9hdXRob3I+PC9h

dXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+Q2xpbiBVbml2IFVDTCBTdCBMdWMs

IEJydXNzZWxzLCBCZWxnaXVtJiN4RDtBc2tsZXBpb3NLbGluIFN0IEdlb3JnLCBBYnQgSGFtYXRv

bCAmYW1wOyBTdGFtbXplbGx0cmFuc3BsYW50YXQsIEhhbWJ1cmcsIEdlcm1hbnkmI3hEO0NIVSBB

cmNoZXQsIE5pY2UsIEZyYW5jZSYjeEQ7UHJpbmNlc3MgQWxleGFuZHJhIEhvc3AsIFdvb2R2aWxs

ZSwgU0EsIEF1c3RyYWxpYSYjeEQ7VUNMLCBJbnN0IENhbmMsIExvbmRvbiwgRW5nbGFuZCYjeEQ7

Q2hhcmxlcyBVbml2IFByYWd1ZSwgR2VuIEhvc3AsIFByYWd1ZSwgQ3plY2ggUmVwdWJsaWMmI3hE

O0hvcCBIYXV0IExldmVxdWUsIEhlbWF0b2wgQ2xpbiAmYW1wOyBUaGVyYXBpZSBDZWxsdWxhaXJl

LCBQZXNzYWMsIEZyYW5jZSYjeEQ7VW5pdiBNYW5jaGVzdGVyLCBDaHJpc3RpZSBIb3NwIE5IUywg

RGVwdCBNZWQgT25jb2wsIE1hbmNoZXN0ZXIsIExhbmNzLCBFbmdsYW5kJiN4RDtDbGluIEJvaXMg

Q2VyZiwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kJiN4RDtBc3N1dGEgTWVkIEN0ciwgVGVsIEF2aXYs

IElzcmFlbCYjeEQ7VW5pdiBLbGluaWt1bSBFc3NlbiwgS2xpbiBIYW1hdG9sLCBFc3NlbiwgR2Vy

bWFueSYjeEQ7U3QgVmluY2VudHMgSG9zcCBTeWRuZXksIERhcmxpbmdodXJzdCwgTlNXLCBBdXN0

cmFsaWEmI3hEO0hvcCBTdCBMb3VpcywgSGVtYXRvb25jb2wgSG9wLCBGLTc1MDEwIFBhcmlzLCBG

cmFuY2UmI3hEO1VuaXYgTHlvbiwgU2VydiBIZW1hdG9sLCBIb3NwIENpdmlscyBMeW9uLCBMeW9u

LCBGcmFuY2UmI3hEO01lbSBTbG9hbiBLZXR0ZXJpbmcgQ2FuYyBDdHIsIDEyNzUgWW9yayBBdmUs

IE5ldyBZb3JrLCBOWSAxMDAyMSBVU0EmI3hEO0hvcCBTdCBMb3VpcywgSGVtYXRvb25jb2wsIDEg

QXZlIENsYXVkZSBWZWxsZWZhdXgsIEYtNzUwMTAgUGFyaXMsIEZyYW5jZTwvYXV0aC1hZGRyZXNz

Pjx0aXRsZXM+PHRpdGxlPk91dGNvbWUgb2YgcGF0aWVudHMgd2l0aCByZWxhcHNlZCBkaWZmdXNl

IGxhcmdlIEItY2VsbCBseW1waG9tYSB3aG8gZmFpbCBzZWNvbmQtbGluZSBzYWx2YWdlIHJlZ2lt

ZW5zIGluIHRoZSBJbnRlcm5hdGlvbmFsIENPUkFMIHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRp

dGxlPkJvbmUgTWFycm93IFRyYW5zcGxhbnRhdGlvbjwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0

bGU+Qm9uZSBNYXJyb3cgVHJhbnNwbDwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPkJvbmUgTWFycm93IFRyYW5zcGxhbnRhdGlvbjwvZnVsbC10aXRsZT48YWJici0x

PkJvbmUgTWFycm93IFRyYW5zcGw8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkJvbmUgTWFycm93IFRyYW5zcGxhbnRhdGlvbjwvZnVsbC10aXRsZT48YWJi

ci0xPkJvbmUgTWFycm93IFRyYW5zcGw8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz41

MS01NzwvcGFnZXM+PHZvbHVtZT41MTwvdm9sdW1lPjxudW1iZXI+MTwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5ub24taG9kZ2tpbi1seW1waG9tYTwva2V5d29yZD48a2V5d29yZD5yaXR1eGlt

YWIgZXJhPC9rZXl3b3JkPjxrZXl3b3JkPmFnZ3Jlc3NpdmUgbHltcGhvbWE8L2tleXdvcmQ+PGtl

eXdvcmQ+cHJvZ25vc3RpYyBpbXBhY3Q8L2tleXdvcmQ+PGtleXdvcmQ+dHJhbnNwbGFudGF0aW9u

PC9rZXl3b3JkPjxrZXl3b3JkPmNoZW1vdGhlcmFweTwva2V5d29yZD48a2V5d29yZD50aGVyYXB5

PC9rZXl3b3JkPjxrZXl3b3JkPnRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPmRleGFtZXRoYXNvbmU8

L2tleXdvcmQ+PGtleXdvcmQ+Y29tYmluYXRpb248L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+

PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48

L2RhdGVzPjxpc2JuPjAyNjgtMzM2OTwvaXNibj48YWNjZXNzaW9uLW51bT5XT1M6MDAwMzY4NDY5

ODAwMDA4PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD4mbHQ7R28gdG8g

SVNJJmd0OzovL1dPUzowMDAzNjg0Njk4MDAwMDg8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMzgvYm10LjIwMTUuMjEzPC9lbGVjdHJvbmlj

LXJlc291cmNlLW51bT48bGFuZ3VhZ2U+RW5nbGlzaDwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRl

PjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYW4gZGVuIE5lc3RlPC9BdXRob3I+PFllYXI+MjAxNjwv

WWVhcj48UmVjTnVtPjU3NTY8L1JlY051bT48RGlzcGxheVRleHQ+KDMpPC9EaXNwbGF5VGV4dD48

cmVjb3JkPjxyZWMtbnVtYmVyPjU3NTY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFw

cD0iRU4iIGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVz

dGFtcD0iMTU3NzEyOTYyMCI+NTc1Njwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1l

PSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh

dXRob3I+VmFuIGRlbiBOZXN0ZSwgRS48L2F1dGhvcj48YXV0aG9yPlNjaG1pdHosIE4uPC9hdXRo

b3I+PGF1dGhvcj5Nb3VuaWVyLCBOLjwvYXV0aG9yPjxhdXRob3I+R2lsbCwgRC48L2F1dGhvcj48

YXV0aG9yPkxpbmNoLCBELjwvYXV0aG9yPjxhdXRob3I+VHJuZW55LCBNLjwvYXV0aG9yPjxhdXRo

b3I+TWlscGllZCwgTi48L2F1dGhvcj48YXV0aG9yPlJhZGZvcmQsIEouPC9hdXRob3I+PGF1dGhv

cj5LZXR0ZXJlciwgTi48L2F1dGhvcj48YXV0aG9yPlNocGlsYmVyZywgTy48L2F1dGhvcj48YXV0

aG9yPkR1aHJzZW4sIFUuPC9hdXRob3I+PGF1dGhvcj5NYSwgRC48L2F1dGhvcj48YXV0aG9yPkJy

aWVyZSwgSi48L2F1dGhvcj48YXV0aG9yPlRoaWVibGVtb250LCBDLjwvYXV0aG9yPjxhdXRob3I+

U2FsbGVzLCBHLjwvYXV0aG9yPjxhdXRob3I+TW9za293aXR6LCBDLiBILjwvYXV0aG9yPjxhdXRo

b3I+R2xhc3MsIEIuPC9hdXRob3I+PGF1dGhvcj5HaXNzZWxicmVjaHQsIEMuPC9hdXRob3I+PC9h

dXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+Q2xpbiBVbml2IFVDTCBTdCBMdWMs

IEJydXNzZWxzLCBCZWxnaXVtJiN4RDtBc2tsZXBpb3NLbGluIFN0IEdlb3JnLCBBYnQgSGFtYXRv

bCAmYW1wOyBTdGFtbXplbGx0cmFuc3BsYW50YXQsIEhhbWJ1cmcsIEdlcm1hbnkmI3hEO0NIVSBB

cmNoZXQsIE5pY2UsIEZyYW5jZSYjeEQ7UHJpbmNlc3MgQWxleGFuZHJhIEhvc3AsIFdvb2R2aWxs

ZSwgU0EsIEF1c3RyYWxpYSYjeEQ7VUNMLCBJbnN0IENhbmMsIExvbmRvbiwgRW5nbGFuZCYjeEQ7

Q2hhcmxlcyBVbml2IFByYWd1ZSwgR2VuIEhvc3AsIFByYWd1ZSwgQ3plY2ggUmVwdWJsaWMmI3hE

O0hvcCBIYXV0IExldmVxdWUsIEhlbWF0b2wgQ2xpbiAmYW1wOyBUaGVyYXBpZSBDZWxsdWxhaXJl

LCBQZXNzYWMsIEZyYW5jZSYjeEQ7VW5pdiBNYW5jaGVzdGVyLCBDaHJpc3RpZSBIb3NwIE5IUywg

RGVwdCBNZWQgT25jb2wsIE1hbmNoZXN0ZXIsIExhbmNzLCBFbmdsYW5kJiN4RDtDbGluIEJvaXMg

Q2VyZiwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kJiN4RDtBc3N1dGEgTWVkIEN0ciwgVGVsIEF2aXYs

IElzcmFlbCYjeEQ7VW5pdiBLbGluaWt1bSBFc3NlbiwgS2xpbiBIYW1hdG9sLCBFc3NlbiwgR2Vy

bWFueSYjeEQ7U3QgVmluY2VudHMgSG9zcCBTeWRuZXksIERhcmxpbmdodXJzdCwgTlNXLCBBdXN0

cmFsaWEmI3hEO0hvcCBTdCBMb3VpcywgSGVtYXRvb25jb2wgSG9wLCBGLTc1MDEwIFBhcmlzLCBG

cmFuY2UmI3hEO1VuaXYgTHlvbiwgU2VydiBIZW1hdG9sLCBIb3NwIENpdmlscyBMeW9uLCBMeW9u

LCBGcmFuY2UmI3hEO01lbSBTbG9hbiBLZXR0ZXJpbmcgQ2FuYyBDdHIsIDEyNzUgWW9yayBBdmUs

IE5ldyBZb3JrLCBOWSAxMDAyMSBVU0EmI3hEO0hvcCBTdCBMb3VpcywgSGVtYXRvb25jb2wsIDEg

QXZlIENsYXVkZSBWZWxsZWZhdXgsIEYtNzUwMTAgUGFyaXMsIEZyYW5jZTwvYXV0aC1hZGRyZXNz

Pjx0aXRsZXM+PHRpdGxlPk91dGNvbWUgb2YgcGF0aWVudHMgd2l0aCByZWxhcHNlZCBkaWZmdXNl

IGxhcmdlIEItY2VsbCBseW1waG9tYSB3aG8gZmFpbCBzZWNvbmQtbGluZSBzYWx2YWdlIHJlZ2lt

ZW5zIGluIHRoZSBJbnRlcm5hdGlvbmFsIENPUkFMIHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRp

dGxlPkJvbmUgTWFycm93IFRyYW5zcGxhbnRhdGlvbjwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0

bGU+Qm9uZSBNYXJyb3cgVHJhbnNwbDwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPkJvbmUgTWFycm93IFRyYW5zcGxhbnRhdGlvbjwvZnVsbC10aXRsZT48YWJici0x

PkJvbmUgTWFycm93IFRyYW5zcGw8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkJvbmUgTWFycm93IFRyYW5zcGxhbnRhdGlvbjwvZnVsbC10aXRsZT48YWJi

ci0xPkJvbmUgTWFycm93IFRyYW5zcGw8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz41

MS01NzwvcGFnZXM+PHZvbHVtZT41MTwvdm9sdW1lPjxudW1iZXI+MTwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5ub24taG9kZ2tpbi1seW1waG9tYTwva2V5d29yZD48a2V5d29yZD5yaXR1eGlt

YWIgZXJhPC9rZXl3b3JkPjxrZXl3b3JkPmFnZ3Jlc3NpdmUgbHltcGhvbWE8L2tleXdvcmQ+PGtl

eXdvcmQ+cHJvZ25vc3RpYyBpbXBhY3Q8L2tleXdvcmQ+PGtleXdvcmQ+dHJhbnNwbGFudGF0aW9u

PC9rZXl3b3JkPjxrZXl3b3JkPmNoZW1vdGhlcmFweTwva2V5d29yZD48a2V5d29yZD50aGVyYXB5

PC9rZXl3b3JkPjxrZXl3b3JkPnRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPmRleGFtZXRoYXNvbmU8

L2tleXdvcmQ+PGtleXdvcmQ+Y29tYmluYXRpb248L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+

PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48

L2RhdGVzPjxpc2JuPjAyNjgtMzM2OTwvaXNibj48YWNjZXNzaW9uLW51bT5XT1M6MDAwMzY4NDY5

ODAwMDA4PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD4mbHQ7R28gdG8g

SVNJJmd0OzovL1dPUzowMDAzNjg0Njk4MDAwMDg8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMzgvYm10LjIwMTUuMjEzPC9lbGVjdHJvbmlj

LXJlc291cmNlLW51bT48bGFuZ3VhZ2U+RW5nbGlzaDwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRl

PjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA (3). Safety and Toxicity of CAR-T Cell Therapy: Unlike chemotherapy-associated side effects, many of the CAR-T cell toxicities resolve only when cells are done expanding, eradicating, or become exhausted. While toxicities are usually manageable and reversible, national data suggest 5-10% of patients have lethal side-effects within the first three months. There is little data about the long-term side effects of CAR-T cell therapy. Safety concerns include:Immune-mediated rejection of normal tissues that express the targeted antigen: also known as “on-target, off-tumor” response (6). For example, a B-cell aplasia induced by CD-19 targeted CARs.Cytokine release syndrome (CRS): high fevers, hypotension, hypoxia, and toxicity of any organ that usually occurs within the first week after CAR-T infusion (8). It is likely due to intense anti-tumor responses by activated T cells. While CRS can bring one to the brink of critical illness, it is usually fully reversible. CRS is common, with rates between 37-93%. Most patients who experience a durable response from CAR-T therapy exhibit at least some degree of CRS, so its presence is interpreted as a good prognostic sign. Patients at high risk of severe CRS include those with bulky tumor burden, comorbidities, and those who develop CRS within 3 days of cell infusion PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYXVkZTwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl

Y051bT41NzE5PC9SZWNOdW0+PERpc3BsYXlUZXh0Pig0KTwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj41NzE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0ienp2ZnhhYXdlcnRmd2xlYWY5YXg5c3o0ZTlkcHcycGF0enZ4IiB0aW1lc3RhbXA9IjE1

NzQ4MDczNDQiIGd1aWQ9ImU1NDAwZjdlLWI4MWItNDJlYS1hMGM3LTg4MzE1NjAyOTQ2MCI+NTcx

OTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3

PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWF1ZGUsIFMuIEwuPC9h

dXRob3I+PGF1dGhvcj5GcmV5LCBOLjwvYXV0aG9yPjxhdXRob3I+U2hhdywgUC4gQS48L2F1dGhv

cj48YXV0aG9yPkFwbGVuYywgUi48L2F1dGhvcj48YXV0aG9yPkJhcnJldHQsIEQuIE0uPC9hdXRo

b3I+PGF1dGhvcj5CdW5pbiwgTi4gSi48L2F1dGhvcj48YXV0aG9yPkNoZXcsIEEuPC9hdXRob3I+

PGF1dGhvcj5Hb256YWxleiwgVi4gRS48L2F1dGhvcj48YXV0aG9yPlpoZW5nLCBaLjwvYXV0aG9y

PjxhdXRob3I+TGFjZXksIFMuIEYuPC9hdXRob3I+PGF1dGhvcj5NYWhua2UsIFkuIEQuPC9hdXRo

b3I+PGF1dGhvcj5NZWxlbmhvcnN0LCBKLiBKLjwvYXV0aG9yPjxhdXRob3I+UmhlaW5nb2xkLCBT

LiBSLjwvYXV0aG9yPjxhdXRob3I+U2hlbiwgQS48L2F1dGhvcj48YXV0aG9yPlRlYWNoZXksIEQu

IFQuPC9hdXRob3I+PGF1dGhvcj5MZXZpbmUsIEIuIEwuPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBD

LiBILjwvYXV0aG9yPjxhdXRob3I+UG9ydGVyLCBELiBMLjwvYXV0aG9yPjxhdXRob3I+R3J1cHAs

IFMuIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RnJv

bSB0aGUgRGl2aXNpb24gb2YgT25jb2xvZ3ksIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBvZiBQ

aGlsYWRlbHBoaWEgKFMuTC5NLiwgUi5BLiwgRC5NLkIuLCBOLkouQi4sIFMuUi5SLiwgRC5ULlQu

LCBTLkEuRy4pLCB0aGUgRGVwYXJ0bWVudHMgb2YgUGVkaWF0cmljcyAoUy5MLk0uLCBSLkEuLCBE

Lk0uQi4sIE4uSi5CLiwgUy5SLlIuLCBELlQuVC4sIFMuQS5HLiksIEJpb3N0YXRpc3RpY3MgYW5k

IEVwaWRlbWlvbG9neSAoUC5BLlMuLCBSLkEuKSwgYW5kIFBhdGhvbG9neSBhbmQgTGFib3JhdG9y

eSBNZWRpY2luZSAoSi5KLk0uLCBCLkwuTC4sIEMuSC5KLiwgUy5BLkcuKSwgdGhlIERpdmlzaW9u

IG9mIEhlbWF0b2xvZ3ktT25jb2xvZ3kgKE4uRi4sIEQuTC5QLiksIGFuZCBBYnJhbXNvbiBDYW5j

ZXIgQ2VudGVyIChOLkYuLCBBLkMuLCBWLkUuRy4sIFouWi4sIFMuRi5MLiwgWS5ELk0uLCBKLkou

TS4sIEIuTC5MLiwgQy5ILkouLCBELkwuUC4sIFMuQS5HLiksIFBlcmVsbWFuIFNjaG9vbCBvZiBN

ZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgLSBhbGwgaW4gUGhpbGFkZWxwaGlh

OyBhbmQgTm92YXJ0aXMgUGhhcm1hY2V1dGljYWxzLCBFYXN0IEhhbm92ZXIsIE5KIChBLlMuKS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5DaGltZXJpYyBhbnRpZ2VuIHJlY2VwdG9yIFQg

Y2VsbHMgZm9yIHN1c3RhaW5lZCByZW1pc3Npb25zIGluIGxldWtlbWlhPC90aXRsZT48c2Vjb25k

YXJ5LXRpdGxlPk4gRW5nbCBKIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2Rp

Y2FsPjxmdWxsLXRpdGxlPk4gRW5nbCBKIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBh

Z2VzPjE1MDctMTc8L3BhZ2VzPjx2b2x1bWU+MzcxPC92b2x1bWU+PG51bWJlcj4xNjwvbnVtYmVy

PjxlZGl0aW9uPjIwMTQvMTAvMTY8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2Nl

bnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWJvZGllcywg

TW9ub2Nsb25hbCwgSHVtYW5pemVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD4q

QW50aWdlbnMsIENEMTk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+

Q2hpbGQsIFByZXNjaG9vbDwva2V5d29yZD48a2V5d29yZD5DaGltZXJhPC9rZXl3b3JkPjxrZXl3

b3JkPkN5dG9raW5lcy9ibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtl

eXdvcmQ+R2VuZXRpYyBFbmdpbmVlcmluZzwva2V5d29yZD48a2V5d29yZD4qR2VuZXRpYyBUaGVy

YXB5PC9rZXl3b3JkPjxrZXl3b3JkPkdlbmV0aWMgVmVjdG9yczwva2V5d29yZD48a2V5d29yZD5I

dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+KkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+

TGVudGl2aXJ1cy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2Js

YXN0aWMgTGV1a2VtaWEtTHltcGhvbWEvaW1tdW5vbG9neS9tb3J0YWxpdHkvKnRoZXJhcHk8L2tl

eXdvcmQ+PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvKnRoZXJh

cGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5SZWN1cnJlbmNlPC9rZXl3b3JkPjxrZXl3b3Jk

PlJlbWlzc2lvbiBJbmR1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5

d29yZD48a2V5d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk

PllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+

PHB1Yi1kYXRlcz48ZGF0ZT5PY3QgMTY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4x

NTMzLTQ0MDYgKEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nl

c3Npb24tbnVtPjI1MzE3ODcwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVy

bD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNTMxNzg3MDwvdXJsPjwvcmVs

YXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM0MjY3NTMxPC9jdXN0b20yPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMDU2L05FSk1vYTE0MDcyMjI8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYXVkZTwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl

Y051bT41NzE5PC9SZWNOdW0+PERpc3BsYXlUZXh0Pig0KTwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj41NzE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0ienp2ZnhhYXdlcnRmd2xlYWY5YXg5c3o0ZTlkcHcycGF0enZ4IiB0aW1lc3RhbXA9IjE1

NzQ4MDczNDQiIGd1aWQ9ImU1NDAwZjdlLWI4MWItNDJlYS1hMGM3LTg4MzE1NjAyOTQ2MCI+NTcx

OTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3

PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWF1ZGUsIFMuIEwuPC9h

dXRob3I+PGF1dGhvcj5GcmV5LCBOLjwvYXV0aG9yPjxhdXRob3I+U2hhdywgUC4gQS48L2F1dGhv

cj48YXV0aG9yPkFwbGVuYywgUi48L2F1dGhvcj48YXV0aG9yPkJhcnJldHQsIEQuIE0uPC9hdXRo

b3I+PGF1dGhvcj5CdW5pbiwgTi4gSi48L2F1dGhvcj48YXV0aG9yPkNoZXcsIEEuPC9hdXRob3I+

PGF1dGhvcj5Hb256YWxleiwgVi4gRS48L2F1dGhvcj48YXV0aG9yPlpoZW5nLCBaLjwvYXV0aG9y

PjxhdXRob3I+TGFjZXksIFMuIEYuPC9hdXRob3I+PGF1dGhvcj5NYWhua2UsIFkuIEQuPC9hdXRo

b3I+PGF1dGhvcj5NZWxlbmhvcnN0LCBKLiBKLjwvYXV0aG9yPjxhdXRob3I+UmhlaW5nb2xkLCBT

LiBSLjwvYXV0aG9yPjxhdXRob3I+U2hlbiwgQS48L2F1dGhvcj48YXV0aG9yPlRlYWNoZXksIEQu

IFQuPC9hdXRob3I+PGF1dGhvcj5MZXZpbmUsIEIuIEwuPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBD

LiBILjwvYXV0aG9yPjxhdXRob3I+UG9ydGVyLCBELiBMLjwvYXV0aG9yPjxhdXRob3I+R3J1cHAs

IFMuIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RnJv

bSB0aGUgRGl2aXNpb24gb2YgT25jb2xvZ3ksIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBvZiBQ

aGlsYWRlbHBoaWEgKFMuTC5NLiwgUi5BLiwgRC5NLkIuLCBOLkouQi4sIFMuUi5SLiwgRC5ULlQu

LCBTLkEuRy4pLCB0aGUgRGVwYXJ0bWVudHMgb2YgUGVkaWF0cmljcyAoUy5MLk0uLCBSLkEuLCBE

Lk0uQi4sIE4uSi5CLiwgUy5SLlIuLCBELlQuVC4sIFMuQS5HLiksIEJpb3N0YXRpc3RpY3MgYW5k

IEVwaWRlbWlvbG9neSAoUC5BLlMuLCBSLkEuKSwgYW5kIFBhdGhvbG9neSBhbmQgTGFib3JhdG9y

eSBNZWRpY2luZSAoSi5KLk0uLCBCLkwuTC4sIEMuSC5KLiwgUy5BLkcuKSwgdGhlIERpdmlzaW9u

IG9mIEhlbWF0b2xvZ3ktT25jb2xvZ3kgKE4uRi4sIEQuTC5QLiksIGFuZCBBYnJhbXNvbiBDYW5j

ZXIgQ2VudGVyIChOLkYuLCBBLkMuLCBWLkUuRy4sIFouWi4sIFMuRi5MLiwgWS5ELk0uLCBKLkou

TS4sIEIuTC5MLiwgQy5ILkouLCBELkwuUC4sIFMuQS5HLiksIFBlcmVsbWFuIFNjaG9vbCBvZiBN

ZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgLSBhbGwgaW4gUGhpbGFkZWxwaGlh

OyBhbmQgTm92YXJ0aXMgUGhhcm1hY2V1dGljYWxzLCBFYXN0IEhhbm92ZXIsIE5KIChBLlMuKS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5DaGltZXJpYyBhbnRpZ2VuIHJlY2VwdG9yIFQg

Y2VsbHMgZm9yIHN1c3RhaW5lZCByZW1pc3Npb25zIGluIGxldWtlbWlhPC90aXRsZT48c2Vjb25k

YXJ5LXRpdGxlPk4gRW5nbCBKIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2Rp

Y2FsPjxmdWxsLXRpdGxlPk4gRW5nbCBKIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBh

Z2VzPjE1MDctMTc8L3BhZ2VzPjx2b2x1bWU+MzcxPC92b2x1bWU+PG51bWJlcj4xNjwvbnVtYmVy

PjxlZGl0aW9uPjIwMTQvMTAvMTY8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2Nl

bnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWJvZGllcywg

TW9ub2Nsb25hbCwgSHVtYW5pemVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD4q

QW50aWdlbnMsIENEMTk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+

Q2hpbGQsIFByZXNjaG9vbDwva2V5d29yZD48a2V5d29yZD5DaGltZXJhPC9rZXl3b3JkPjxrZXl3

b3JkPkN5dG9raW5lcy9ibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtl

eXdvcmQ+R2VuZXRpYyBFbmdpbmVlcmluZzwva2V5d29yZD48a2V5d29yZD4qR2VuZXRpYyBUaGVy

YXB5PC9rZXl3b3JkPjxrZXl3b3JkPkdlbmV0aWMgVmVjdG9yczwva2V5d29yZD48a2V5d29yZD5I

dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+KkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+

TGVudGl2aXJ1cy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2Js

YXN0aWMgTGV1a2VtaWEtTHltcGhvbWEvaW1tdW5vbG9neS9tb3J0YWxpdHkvKnRoZXJhcHk8L2tl

eXdvcmQ+PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvKnRoZXJh

cGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5SZWN1cnJlbmNlPC9rZXl3b3JkPjxrZXl3b3Jk

PlJlbWlzc2lvbiBJbmR1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5

d29yZD48a2V5d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk

PllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+

PHB1Yi1kYXRlcz48ZGF0ZT5PY3QgMTY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4x

NTMzLTQ0MDYgKEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nl

c3Npb24tbnVtPjI1MzE3ODcwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVy

bD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNTMxNzg3MDwvdXJsPjwvcmVs

YXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM0MjY3NTMxPC9jdXN0b20yPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMDU2L05FSk1vYTE0MDcyMjI8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE.DATA (4). The rates of severe CRS are 1-23% for patients with lymphoma and 23-46% for patients with ALL, with nearly half of those enrolled in the early CAR-T trials requiring intensive care management PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYW50b21hc3NvPC9BdXRob3I+PFllYXI+MjAxOTwvWWVh

cj48UmVjTnVtPjU3MDg8L1JlY051bT48RGlzcGxheVRleHQ+KDUpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjU3MDg8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0i

RU4iIGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVzdGFt

cD0iMTU3NDgwNzEwMSIgZ3VpZD0iMGYwNTEzODUtYjMwMS00NzQ2LWIyMTQtNTc0NDIwOTY2MGI4

Ij41NzA4PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNs

ZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TYW50b21hc3Nv

LCBCLjwvYXV0aG9yPjxhdXRob3I+QmFjaGllciwgQy48L2F1dGhvcj48YXV0aG9yPldlc3Rpbiwg

Si48L2F1dGhvcj48YXV0aG9yPlJlenZhbmksIEsuPC9hdXRob3I+PGF1dGhvcj5TaHBhbGwsIEUu

IEouPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+MSBNZW1v

cmlhbCBTbG9hbiBLZXR0ZXJpbmcgQ2FuY2VyIENlbnRlciwgTmV3IFlvcmssIE5ZLiYjeEQ7MiBT

YXJhaCBDYW5ub24gQ2VudGVyIGZvciBCbG9vZCBDYW5jZXIsIE5hc2h2aWxsZSwgVE4uJiN4RDsz

IFRoZSBVbml2ZXJzaXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIEhvdXN0

b24sIFRYLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRoZSBPdGhlciBTaWRlIG9mIENB

UiBULUNlbGwgVGhlcmFweTogQ3l0b2tpbmUgUmVsZWFzZSBTeW5kcm9tZSwgTmV1cm9sb2dpYyBU

b3hpY2l0eSwgYW5kIEZpbmFuY2lhbCBCdXJkZW48L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0g

U29jIENsaW4gT25jb2wgRWR1YyBCb29rPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+QW0gU29jIENsaW4gT25jb2wgRWR1YyBCb29rPC9mdWxsLXRpdGxl

PjwvcGVyaW9kaWNhbD48cGFnZXM+NDMzLTQ0NDwvcGFnZXM+PHZvbHVtZT4zOTwvdm9sdW1lPjxl

ZGl0aW9uPjIwMTkvMDUvMTg8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPipDb3N0IG9mIEls

bG5lc3M8L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZSBNYW5hZ2VtZW50PC9rZXl3b3JkPjxrZXl3

b3JkPkdlbmV0aWMgRW5naW5lZXJpbmc8L2tleXdvcmQ+PGtleXdvcmQ+SGVtYXRvbG9naWMgTmVv

cGxhc21zLypjb21wbGljYXRpb25zLyplcGlkZW1pb2xvZ3kvaW1tdW5vbG9neS90aGVyYXB5PC9r

ZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5LCBB

ZG9wdGl2ZS8qYWR2ZXJzZSBlZmZlY3RzL21ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+TmVydm91

cyBTeXN0ZW0gRGlzZWFzZXMvZGlhZ25vc2lzL2VwaWRlbWlvbG9neS8qZXRpb2xvZ3k8L2tleXdv

cmQ+PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvbWV0YWJvbGlz

bTwva2V5d29yZD48a2V5d29yZD5SZWNlcHRvcnMsIENoaW1lcmljIEFudGlnZW4vZ2VuZXRpY3M8

L2tleXdvcmQ+PGtleXdvcmQ+U2V2ZXJpdHkgb2YgSWxsbmVzcyBJbmRleDwva2V5d29yZD48a2V5

d29yZD5ULUx5bXBob2N5dGVzL2ltbXVub2xvZ3kvbWV0YWJvbGlzbTwva2V5d29yZD48a2V5d29y

ZD5UcmVhdG1lbnQgT3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE5

PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlz

Ym4+MTU0OC04NzU2IChFbGVjdHJvbmljKSYjeEQ7MTU0OC04NzQ4IChMaW5raW5nKTwvaXNibj48

YWNjZXNzaW9uLW51bT4zMTA5OTY5NDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxz

Pjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzEwOTk2OTQ8L3VybD48

L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEyMDAvRURC

S18yMzg2OTE8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5v

dGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYW50b21hc3NvPC9BdXRob3I+PFllYXI+MjAxOTwvWWVh

cj48UmVjTnVtPjU3MDg8L1JlY051bT48RGlzcGxheVRleHQ+KDUpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjU3MDg8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0i

RU4iIGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVzdGFt

cD0iMTU3NDgwNzEwMSIgZ3VpZD0iMGYwNTEzODUtYjMwMS00NzQ2LWIyMTQtNTc0NDIwOTY2MGI4

Ij41NzA4PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNs

ZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TYW50b21hc3Nv

LCBCLjwvYXV0aG9yPjxhdXRob3I+QmFjaGllciwgQy48L2F1dGhvcj48YXV0aG9yPldlc3Rpbiwg

Si48L2F1dGhvcj48YXV0aG9yPlJlenZhbmksIEsuPC9hdXRob3I+PGF1dGhvcj5TaHBhbGwsIEUu

IEouPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+MSBNZW1v

cmlhbCBTbG9hbiBLZXR0ZXJpbmcgQ2FuY2VyIENlbnRlciwgTmV3IFlvcmssIE5ZLiYjeEQ7MiBT

YXJhaCBDYW5ub24gQ2VudGVyIGZvciBCbG9vZCBDYW5jZXIsIE5hc2h2aWxsZSwgVE4uJiN4RDsz

IFRoZSBVbml2ZXJzaXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIEhvdXN0

b24sIFRYLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRoZSBPdGhlciBTaWRlIG9mIENB

UiBULUNlbGwgVGhlcmFweTogQ3l0b2tpbmUgUmVsZWFzZSBTeW5kcm9tZSwgTmV1cm9sb2dpYyBU

b3hpY2l0eSwgYW5kIEZpbmFuY2lhbCBCdXJkZW48L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0g

U29jIENsaW4gT25jb2wgRWR1YyBCb29rPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+QW0gU29jIENsaW4gT25jb2wgRWR1YyBCb29rPC9mdWxsLXRpdGxl

PjwvcGVyaW9kaWNhbD48cGFnZXM+NDMzLTQ0NDwvcGFnZXM+PHZvbHVtZT4zOTwvdm9sdW1lPjxl

ZGl0aW9uPjIwMTkvMDUvMTg8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPipDb3N0IG9mIEls

bG5lc3M8L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZSBNYW5hZ2VtZW50PC9rZXl3b3JkPjxrZXl3

b3JkPkdlbmV0aWMgRW5naW5lZXJpbmc8L2tleXdvcmQ+PGtleXdvcmQ+SGVtYXRvbG9naWMgTmVv

cGxhc21zLypjb21wbGljYXRpb25zLyplcGlkZW1pb2xvZ3kvaW1tdW5vbG9neS90aGVyYXB5PC9r

ZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5LCBB

ZG9wdGl2ZS8qYWR2ZXJzZSBlZmZlY3RzL21ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+TmVydm91

cyBTeXN0ZW0gRGlzZWFzZXMvZGlhZ25vc2lzL2VwaWRlbWlvbG9neS8qZXRpb2xvZ3k8L2tleXdv

cmQ+PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvbWV0YWJvbGlz

bTwva2V5d29yZD48a2V5d29yZD5SZWNlcHRvcnMsIENoaW1lcmljIEFudGlnZW4vZ2VuZXRpY3M8

L2tleXdvcmQ+PGtleXdvcmQ+U2V2ZXJpdHkgb2YgSWxsbmVzcyBJbmRleDwva2V5d29yZD48a2V5

d29yZD5ULUx5bXBob2N5dGVzL2ltbXVub2xvZ3kvbWV0YWJvbGlzbTwva2V5d29yZD48a2V5d29y

ZD5UcmVhdG1lbnQgT3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE5

PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlz

Ym4+MTU0OC04NzU2IChFbGVjdHJvbmljKSYjeEQ7MTU0OC04NzQ4IChMaW5raW5nKTwvaXNibj48

YWNjZXNzaW9uLW51bT4zMTA5OTY5NDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxz

Pjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzEwOTk2OTQ8L3VybD48

L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEyMDAvRURC

S18yMzg2OTE8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5v

dGU+

ADDIN EN.CITE.DATA (5). Management of severe CRS remains challenging, given the delicate balance of mitigating uncontrolled inflammation without dampening antitumor efficacy. While oncologists may try to avoid corticosteroids to preserve antitumor efficacy, they may be necessary for severe cases as may vasopressors and specialized medications such as tocilizumab or anakinra PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48

UmVjTnVtPjU3MDY8L1JlY051bT48RGlzcGxheVRleHQ+KDYpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjU3MDY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVzdGFtcD0i

MTU3NDgwNzAzNiIgZ3VpZD0iNzRkNTk1ZGQtYmI3Mi00NDJjLWFmMjAtNDE2NTQ3ODBhZjIyIj41

NzA2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+

MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OZWVsYXB1LCBTLiBT

LjwvYXV0aG9yPjxhdXRob3I+VHVtbWFsYSwgUy48L2F1dGhvcj48YXV0aG9yPktlYnJpYWVpLCBQ

LjwvYXV0aG9yPjxhdXRob3I+V2llcmRhLCBXLjwvYXV0aG9yPjxhdXRob3I+R3V0aWVycmV6LCBD

LjwvYXV0aG9yPjxhdXRob3I+TG9ja2UsIEYuIEwuPC9hdXRob3I+PGF1dGhvcj5Lb21hbmR1cmks

IEsuIFYuPC9hdXRob3I+PGF1dGhvcj5MaW4sIFkuPC9hdXRob3I+PGF1dGhvcj5KYWluLCBOLjwv

YXV0aG9yPjxhdXRob3I+RGF2ZXIsIE4uPC9hdXRob3I+PGF1dGhvcj5XZXN0aW4sIEouPC9hdXRo

b3I+PGF1dGhvcj5HdWxiaXMsIEEuIE0uPC9hdXRob3I+PGF1dGhvcj5Mb2doaW4sIE0uIEUuPC9h

dXRob3I+PGF1dGhvcj5kZSBHcm9vdCwgSi4gRi48L2F1dGhvcj48YXV0aG9yPkFka2lucywgUy48

L2F1dGhvcj48YXV0aG9yPkRhdmlzLCBTLiBFLjwvYXV0aG9yPjxhdXRob3I+UmV6dmFuaSwgSy48

L2F1dGhvcj48YXV0aG9yPkh3dSwgUC48L2F1dGhvcj48YXV0aG9yPlNocGFsbCwgRS4gSi48L2F1

dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9m

IEx5bXBob21hIGFuZCBNeWVsb21hLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNv

biBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMg

NzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm8tT25jb2xvZ3ksIFRoZSBVbml2ZXJz

aXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1MTUgSG9sY29tYmUgQm91

bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBTdGVt

IENlbGwgVHJhbnNwbGFudGF0aW9uIGFuZCBDZWxsdWxhciBUaGVyYXB5LCBUaGUgVW5pdmVyc2l0

eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxl

dmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTGV1a2Vt

aWEsIFRoZSBVbml2ZXJzaXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1

MTUgSG9sY29tYmUgQm91bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVw

YXJ0bWVudCBvZiBDcml0aWNhbCBDYXJlLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRl

cnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4

YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgQmxvb2QgYW5kIE1hcnJvdyBUcmFuc3Bs

YW50YXRpb24gYW5kIENlbGx1bGFyIEltbXVub3RoZXJhcHksIE1vZmZpdHQgQ2FuY2VyIENlbnRl

ciwgMTI5MDIgVVNGIE1hZ25vbGlhIERyaXZlLCBUYW1wYSwgRmxvcmlkYSAzMzYxMywgVVNBLiYj

eEQ7QWR1bHQgU3RlbSBDZWxsIFRyYW5zcGxhbnQgUHJvZ3JhbSwgU3lsdmVzdGVyIENvbXByZWhl

bnNpdmUgQ2FuY2VyIENlbnRlciwgVW5pdmVyc2l0eSBvZiBNaWFtaSwgMTQ3NSBOb3J0aHdlc3Qg

MTIgdGggQXZlbnVlLCBNaWFtaSwgRmxvcmlkYSAzMzEzNiwgVVNBLiYjeEQ7RGl2aXNpb24gb2Yg

SGVtYXRvbG9neSwgTWF5byBDbGluaWMsIDIwMCBGaXJzdCBTdHJlZXQgU291dGggV2VzdCwgUm9j

aGVzdGVyLCBNaW5uZXNvdGEgNTU5MDUsIFVTQS4mI3hEO0RpdmlzaW9uIG9mIFBoYXJtYWN5LCBU

aGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhv

bGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RpdmlzaW9u

IG9mIENhbmNlciBNZWRpY2luZSwgVGhlIFVuaXZlcnNpdHkgb2YgVGV4YXMgTUQgQW5kZXJzb24g

Q2FuY2VyIENlbnRlciwgMTUxNSBIb2xjb21iZSBCb3VsZXZhcmQsIEhvdXN0b24sIFRleGFzIDc3

MDMwLCBVU0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+Q2hpbWVyaWMgYW50aWdlbiBy

ZWNlcHRvciBULWNlbGwgdGhlcmFweSAtIGFzc2Vzc21lbnQgYW5kIG1hbmFnZW1lbnQgb2YgdG94

aWNpdGllczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5OYXQgUmV2IENsaW4gT25jb2w8L3NlY29u

ZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OYXQgUmV2IENsaW4g

T25jb2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz40Ny02MjwvcGFnZXM+PHZvbHVt

ZT4xNTwvdm9sdW1lPjxudW1iZXI+MTwvbnVtYmVyPjxlZGl0aW9uPjIwMTcvMDkvMjA8L2VkaXRp

b24+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkJyYWluIERpc2Vh

c2VzL2V0aW9sb2d5L3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Q3l0b2tpbmVzL21ldGFib2xp

c208L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5

d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5LCBBZG9wdGl2ZS8qYWR2ZXJzZSBlZmZlY3RzPC9r

ZXl3b3JkPjxrZXl3b3JkPlJlY2VwdG9ycywgQW50aWdlbiwgVC1DZWxsLyppbW11bm9sb2d5L3Ro

ZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5TeW5kcm9tZTwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDE4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc1OS00NzgyIChFbGVjdHJvbmljKSYjeEQ7MTc1OS00

Nzc0IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yODkyNTk5NDwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9w

dWJtZWQvMjg5MjU5OTQ8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNjcz

MzQwMzwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAzOC9ucmNsaW5vbmMu

MjAxNy4xNDg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5v

dGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48

UmVjTnVtPjU3MDY8L1JlY051bT48RGlzcGxheVRleHQ+KDYpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjU3MDY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVzdGFtcD0i

MTU3NDgwNzAzNiIgZ3VpZD0iNzRkNTk1ZGQtYmI3Mi00NDJjLWFmMjAtNDE2NTQ3ODBhZjIyIj41

NzA2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+

MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OZWVsYXB1LCBTLiBT

LjwvYXV0aG9yPjxhdXRob3I+VHVtbWFsYSwgUy48L2F1dGhvcj48YXV0aG9yPktlYnJpYWVpLCBQ

LjwvYXV0aG9yPjxhdXRob3I+V2llcmRhLCBXLjwvYXV0aG9yPjxhdXRob3I+R3V0aWVycmV6LCBD

LjwvYXV0aG9yPjxhdXRob3I+TG9ja2UsIEYuIEwuPC9hdXRob3I+PGF1dGhvcj5Lb21hbmR1cmks

IEsuIFYuPC9hdXRob3I+PGF1dGhvcj5MaW4sIFkuPC9hdXRob3I+PGF1dGhvcj5KYWluLCBOLjwv

YXV0aG9yPjxhdXRob3I+RGF2ZXIsIE4uPC9hdXRob3I+PGF1dGhvcj5XZXN0aW4sIEouPC9hdXRo

b3I+PGF1dGhvcj5HdWxiaXMsIEEuIE0uPC9hdXRob3I+PGF1dGhvcj5Mb2doaW4sIE0uIEUuPC9h

dXRob3I+PGF1dGhvcj5kZSBHcm9vdCwgSi4gRi48L2F1dGhvcj48YXV0aG9yPkFka2lucywgUy48

L2F1dGhvcj48YXV0aG9yPkRhdmlzLCBTLiBFLjwvYXV0aG9yPjxhdXRob3I+UmV6dmFuaSwgSy48

L2F1dGhvcj48YXV0aG9yPkh3dSwgUC48L2F1dGhvcj48YXV0aG9yPlNocGFsbCwgRS4gSi48L2F1

dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9m

IEx5bXBob21hIGFuZCBNeWVsb21hLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNv

biBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMg

NzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm8tT25jb2xvZ3ksIFRoZSBVbml2ZXJz

aXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1MTUgSG9sY29tYmUgQm91

bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBTdGVt

IENlbGwgVHJhbnNwbGFudGF0aW9uIGFuZCBDZWxsdWxhciBUaGVyYXB5LCBUaGUgVW5pdmVyc2l0

eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxl

dmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTGV1a2Vt

aWEsIFRoZSBVbml2ZXJzaXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1

MTUgSG9sY29tYmUgQm91bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVw

YXJ0bWVudCBvZiBDcml0aWNhbCBDYXJlLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRl

cnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4

YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgQmxvb2QgYW5kIE1hcnJvdyBUcmFuc3Bs

YW50YXRpb24gYW5kIENlbGx1bGFyIEltbXVub3RoZXJhcHksIE1vZmZpdHQgQ2FuY2VyIENlbnRl

ciwgMTI5MDIgVVNGIE1hZ25vbGlhIERyaXZlLCBUYW1wYSwgRmxvcmlkYSAzMzYxMywgVVNBLiYj

eEQ7QWR1bHQgU3RlbSBDZWxsIFRyYW5zcGxhbnQgUHJvZ3JhbSwgU3lsdmVzdGVyIENvbXByZWhl

bnNpdmUgQ2FuY2VyIENlbnRlciwgVW5pdmVyc2l0eSBvZiBNaWFtaSwgMTQ3NSBOb3J0aHdlc3Qg

MTIgdGggQXZlbnVlLCBNaWFtaSwgRmxvcmlkYSAzMzEzNiwgVVNBLiYjeEQ7RGl2aXNpb24gb2Yg

SGVtYXRvbG9neSwgTWF5byBDbGluaWMsIDIwMCBGaXJzdCBTdHJlZXQgU291dGggV2VzdCwgUm9j

aGVzdGVyLCBNaW5uZXNvdGEgNTU5MDUsIFVTQS4mI3hEO0RpdmlzaW9uIG9mIFBoYXJtYWN5LCBU

aGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhv

bGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RpdmlzaW9u

IG9mIENhbmNlciBNZWRpY2luZSwgVGhlIFVuaXZlcnNpdHkgb2YgVGV4YXMgTUQgQW5kZXJzb24g

Q2FuY2VyIENlbnRlciwgMTUxNSBIb2xjb21iZSBCb3VsZXZhcmQsIEhvdXN0b24sIFRleGFzIDc3

MDMwLCBVU0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+Q2hpbWVyaWMgYW50aWdlbiBy

ZWNlcHRvciBULWNlbGwgdGhlcmFweSAtIGFzc2Vzc21lbnQgYW5kIG1hbmFnZW1lbnQgb2YgdG94

aWNpdGllczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5OYXQgUmV2IENsaW4gT25jb2w8L3NlY29u

ZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OYXQgUmV2IENsaW4g

T25jb2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz40Ny02MjwvcGFnZXM+PHZvbHVt

ZT4xNTwvdm9sdW1lPjxudW1iZXI+MTwvbnVtYmVyPjxlZGl0aW9uPjIwMTcvMDkvMjA8L2VkaXRp

b24+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkJyYWluIERpc2Vh

c2VzL2V0aW9sb2d5L3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Q3l0b2tpbmVzL21ldGFib2xp

c208L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5

d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5LCBBZG9wdGl2ZS8qYWR2ZXJzZSBlZmZlY3RzPC9r

ZXl3b3JkPjxrZXl3b3JkPlJlY2VwdG9ycywgQW50aWdlbiwgVC1DZWxsLyppbW11bm9sb2d5L3Ro

ZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5TeW5kcm9tZTwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDE4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc1OS00NzgyIChFbGVjdHJvbmljKSYjeEQ7MTc1OS00

Nzc0IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yODkyNTk5NDwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9w

dWJtZWQvMjg5MjU5OTQ8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNjcz

MzQwMzwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAzOC9ucmNsaW5vbmMu

MjAxNy4xNDg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5v

dGU+AG==

ADDIN EN.CITE.DATA (6). CAR-T-cell related immune effector cell-associated neurotoxicity syndrome (ICANS) is characterized by global encephalopathy, aphasia, seizure/seizure-like activity, obtundation, tremor/myoclonus, and hallucinations PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48

UmVjTnVtPjU3MDY8L1JlY051bT48RGlzcGxheVRleHQ+KDYpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjU3MDY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVzdGFtcD0i

MTU3NDgwNzAzNiIgZ3VpZD0iNzRkNTk1ZGQtYmI3Mi00NDJjLWFmMjAtNDE2NTQ3ODBhZjIyIj41

NzA2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+

MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OZWVsYXB1LCBTLiBT

LjwvYXV0aG9yPjxhdXRob3I+VHVtbWFsYSwgUy48L2F1dGhvcj48YXV0aG9yPktlYnJpYWVpLCBQ

LjwvYXV0aG9yPjxhdXRob3I+V2llcmRhLCBXLjwvYXV0aG9yPjxhdXRob3I+R3V0aWVycmV6LCBD

LjwvYXV0aG9yPjxhdXRob3I+TG9ja2UsIEYuIEwuPC9hdXRob3I+PGF1dGhvcj5Lb21hbmR1cmks

IEsuIFYuPC9hdXRob3I+PGF1dGhvcj5MaW4sIFkuPC9hdXRob3I+PGF1dGhvcj5KYWluLCBOLjwv

YXV0aG9yPjxhdXRob3I+RGF2ZXIsIE4uPC9hdXRob3I+PGF1dGhvcj5XZXN0aW4sIEouPC9hdXRo

b3I+PGF1dGhvcj5HdWxiaXMsIEEuIE0uPC9hdXRob3I+PGF1dGhvcj5Mb2doaW4sIE0uIEUuPC9h

dXRob3I+PGF1dGhvcj5kZSBHcm9vdCwgSi4gRi48L2F1dGhvcj48YXV0aG9yPkFka2lucywgUy48

L2F1dGhvcj48YXV0aG9yPkRhdmlzLCBTLiBFLjwvYXV0aG9yPjxhdXRob3I+UmV6dmFuaSwgSy48

L2F1dGhvcj48YXV0aG9yPkh3dSwgUC48L2F1dGhvcj48YXV0aG9yPlNocGFsbCwgRS4gSi48L2F1

dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9m

IEx5bXBob21hIGFuZCBNeWVsb21hLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNv

biBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMg

NzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm8tT25jb2xvZ3ksIFRoZSBVbml2ZXJz

aXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1MTUgSG9sY29tYmUgQm91

bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBTdGVt

IENlbGwgVHJhbnNwbGFudGF0aW9uIGFuZCBDZWxsdWxhciBUaGVyYXB5LCBUaGUgVW5pdmVyc2l0

eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxl

dmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTGV1a2Vt

aWEsIFRoZSBVbml2ZXJzaXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1

MTUgSG9sY29tYmUgQm91bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVw

YXJ0bWVudCBvZiBDcml0aWNhbCBDYXJlLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRl

cnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4

YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgQmxvb2QgYW5kIE1hcnJvdyBUcmFuc3Bs

YW50YXRpb24gYW5kIENlbGx1bGFyIEltbXVub3RoZXJhcHksIE1vZmZpdHQgQ2FuY2VyIENlbnRl

ciwgMTI5MDIgVVNGIE1hZ25vbGlhIERyaXZlLCBUYW1wYSwgRmxvcmlkYSAzMzYxMywgVVNBLiYj

eEQ7QWR1bHQgU3RlbSBDZWxsIFRyYW5zcGxhbnQgUHJvZ3JhbSwgU3lsdmVzdGVyIENvbXByZWhl

bnNpdmUgQ2FuY2VyIENlbnRlciwgVW5pdmVyc2l0eSBvZiBNaWFtaSwgMTQ3NSBOb3J0aHdlc3Qg

MTIgdGggQXZlbnVlLCBNaWFtaSwgRmxvcmlkYSAzMzEzNiwgVVNBLiYjeEQ7RGl2aXNpb24gb2Yg

SGVtYXRvbG9neSwgTWF5byBDbGluaWMsIDIwMCBGaXJzdCBTdHJlZXQgU291dGggV2VzdCwgUm9j

aGVzdGVyLCBNaW5uZXNvdGEgNTU5MDUsIFVTQS4mI3hEO0RpdmlzaW9uIG9mIFBoYXJtYWN5LCBU

aGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhv

bGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RpdmlzaW9u

IG9mIENhbmNlciBNZWRpY2luZSwgVGhlIFVuaXZlcnNpdHkgb2YgVGV4YXMgTUQgQW5kZXJzb24g

Q2FuY2VyIENlbnRlciwgMTUxNSBIb2xjb21iZSBCb3VsZXZhcmQsIEhvdXN0b24sIFRleGFzIDc3

MDMwLCBVU0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+Q2hpbWVyaWMgYW50aWdlbiBy

ZWNlcHRvciBULWNlbGwgdGhlcmFweSAtIGFzc2Vzc21lbnQgYW5kIG1hbmFnZW1lbnQgb2YgdG94

aWNpdGllczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5OYXQgUmV2IENsaW4gT25jb2w8L3NlY29u

ZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OYXQgUmV2IENsaW4g

T25jb2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz40Ny02MjwvcGFnZXM+PHZvbHVt

ZT4xNTwvdm9sdW1lPjxudW1iZXI+MTwvbnVtYmVyPjxlZGl0aW9uPjIwMTcvMDkvMjA8L2VkaXRp

b24+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkJyYWluIERpc2Vh

c2VzL2V0aW9sb2d5L3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Q3l0b2tpbmVzL21ldGFib2xp

c208L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5

d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5LCBBZG9wdGl2ZS8qYWR2ZXJzZSBlZmZlY3RzPC9r

ZXl3b3JkPjxrZXl3b3JkPlJlY2VwdG9ycywgQW50aWdlbiwgVC1DZWxsLyppbW11bm9sb2d5L3Ro

ZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5TeW5kcm9tZTwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDE4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc1OS00NzgyIChFbGVjdHJvbmljKSYjeEQ7MTc1OS00

Nzc0IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yODkyNTk5NDwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9w

dWJtZWQvMjg5MjU5OTQ8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNjcz

MzQwMzwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAzOC9ucmNsaW5vbmMu

MjAxNy4xNDg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5v

dGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48

UmVjTnVtPjU3MDY8L1JlY051bT48RGlzcGxheVRleHQ+KDYpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjU3MDY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJ6enZmeGFhd2VydGZ3bGVhZjlheDlzejRlOWRwdzJwYXR6dngiIHRpbWVzdGFtcD0i

MTU3NDgwNzAzNiIgZ3VpZD0iNzRkNTk1ZGQtYmI3Mi00NDJjLWFmMjAtNDE2NTQ3ODBhZjIyIj41

NzA2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+

MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OZWVsYXB1LCBTLiBT

LjwvYXV0aG9yPjxhdXRob3I+VHVtbWFsYSwgUy48L2F1dGhvcj48YXV0aG9yPktlYnJpYWVpLCBQ

LjwvYXV0aG9yPjxhdXRob3I+V2llcmRhLCBXLjwvYXV0aG9yPjxhdXRob3I+R3V0aWVycmV6LCBD

LjwvYXV0aG9yPjxhdXRob3I+TG9ja2UsIEYuIEwuPC9hdXRob3I+PGF1dGhvcj5Lb21hbmR1cmks

IEsuIFYuPC9hdXRob3I+PGF1dGhvcj5MaW4sIFkuPC9hdXRob3I+PGF1dGhvcj5KYWluLCBOLjwv

YXV0aG9yPjxhdXRob3I+RGF2ZXIsIE4uPC9hdXRob3I+PGF1dGhvcj5XZXN0aW4sIEouPC9hdXRo

b3I+PGF1dGhvcj5HdWxiaXMsIEEuIE0uPC9hdXRob3I+PGF1dGhvcj5Mb2doaW4sIE0uIEUuPC9h

dXRob3I+PGF1dGhvcj5kZSBHcm9vdCwgSi4gRi48L2F1dGhvcj48YXV0aG9yPkFka2lucywgUy48

L2F1dGhvcj48YXV0aG9yPkRhdmlzLCBTLiBFLjwvYXV0aG9yPjxhdXRob3I+UmV6dmFuaSwgSy48

L2F1dGhvcj48YXV0aG9yPkh3dSwgUC48L2F1dGhvcj48YXV0aG9yPlNocGFsbCwgRS4gSi48L2F1

dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9m

IEx5bXBob21hIGFuZCBNeWVsb21hLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNv

biBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMg

NzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm8tT25jb2xvZ3ksIFRoZSBVbml2ZXJz

aXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1MTUgSG9sY29tYmUgQm91

bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBTdGVt

IENlbGwgVHJhbnNwbGFudGF0aW9uIGFuZCBDZWxsdWxhciBUaGVyYXB5LCBUaGUgVW5pdmVyc2l0

eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxl

dmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTGV1a2Vt

aWEsIFRoZSBVbml2ZXJzaXR5IG9mIFRleGFzIE1EIEFuZGVyc29uIENhbmNlciBDZW50ZXIsIDE1

MTUgSG9sY29tYmUgQm91bGV2YXJkLCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBLiYjeEQ7RGVw

YXJ0bWVudCBvZiBDcml0aWNhbCBDYXJlLCBUaGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRl

cnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhvbGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4

YXMgNzcwMzAsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgQmxvb2QgYW5kIE1hcnJvdyBUcmFuc3Bs

YW50YXRpb24gYW5kIENlbGx1bGFyIEltbXVub3RoZXJhcHksIE1vZmZpdHQgQ2FuY2VyIENlbnRl

ciwgMTI5MDIgVVNGIE1hZ25vbGlhIERyaXZlLCBUYW1wYSwgRmxvcmlkYSAzMzYxMywgVVNBLiYj

eEQ7QWR1bHQgU3RlbSBDZWxsIFRyYW5zcGxhbnQgUHJvZ3JhbSwgU3lsdmVzdGVyIENvbXByZWhl

bnNpdmUgQ2FuY2VyIENlbnRlciwgVW5pdmVyc2l0eSBvZiBNaWFtaSwgMTQ3NSBOb3J0aHdlc3Qg

MTIgdGggQXZlbnVlLCBNaWFtaSwgRmxvcmlkYSAzMzEzNiwgVVNBLiYjeEQ7RGl2aXNpb24gb2Yg

SGVtYXRvbG9neSwgTWF5byBDbGluaWMsIDIwMCBGaXJzdCBTdHJlZXQgU291dGggV2VzdCwgUm9j

aGVzdGVyLCBNaW5uZXNvdGEgNTU5MDUsIFVTQS4mI3hEO0RpdmlzaW9uIG9mIFBoYXJtYWN5LCBU

aGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBNRCBBbmRlcnNvbiBDYW5jZXIgQ2VudGVyLCAxNTE1IEhv

bGNvbWJlIEJvdWxldmFyZCwgSG91c3RvbiwgVGV4YXMgNzcwMzAsIFVTQS4mI3hEO0RpdmlzaW9u

IG9mIENhbmNlciBNZWRpY2luZSwgVGhlIFVuaXZlcnNpdHkgb2YgVGV4YXMgTUQgQW5kZXJzb24g

Q2FuY2VyIENlbnRlciwgMTUxNSBIb2xjb21iZSBCb3VsZXZhcmQsIEhvdXN0b24sIFRleGFzIDc3

MDMwLCBVU0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+Q2hpbWVyaWMgYW50aWdlbiBy

ZWNlcHRvciBULWNlbGwgdGhlcmFweSAtIGFzc2Vzc21lbnQgYW5kIG1hbmFnZW1lbnQgb2YgdG94

aWNpdGllczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5OYXQgUmV2IENsaW4gT25jb2w8L3NlY29u

ZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OYXQgUmV2IENsaW4g

T25jb2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz40Ny02MjwvcGFnZXM+PHZvbHVt

ZT4xNTwvdm9sdW1lPjxudW1iZXI+MTwvbnVtYmVyPjxlZGl0aW9uPjIwMTcvMDkvMjA8L2VkaXRp

b24+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkJyYWluIERpc2Vh

c2VzL2V0aW9sb2d5L3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Q3l0b2tpbmVzL21ldGFib2xp

c208L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5

d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5LCBBZG9wdGl2ZS8qYWR2ZXJzZSBlZmZlY3RzPC9r

ZXl3b3JkPjxrZXl3b3JkPlJlY2VwdG9ycywgQW50aWdlbiwgVC1DZWxsLyppbW11bm9sb2d5L3Ro

ZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5TeW5kcm9tZTwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDE4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc1OS00NzgyIChFbGVjdHJvbmljKSYjeEQ7MTc1OS00

Nzc0IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yODkyNTk5NDwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9w

dWJtZWQvMjg5MjU5OTQ8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNjcz

MzQwMzwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAzOC9ucmNsaW5vbmMu

MjAxNy4xNDg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5v

dGU+AG==

ADDIN EN.CITE.DATA (6). Rates of severe ICANS are 12–30% for patients with lymphoma and 13–42% for patients with leukemia. Clinical factors impacting the risk of ICANS include marrow disease, higher CAR T-cell dose, prior severe CRS, and pre-existing neurologic comorbidities. While ICANS is often reversible, permanent neurologic side-effects and fatalities have resulted from ICANS.Cost: The price of CAR T-cell therapy approximates $500,000 ADDIN EN.CITE <EndNote><Cite><Author>Green</Author><Year>2018</Year><RecNum>5731</RecNum><DisplayText>(7)</DisplayText><record><rec-number>5731</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1577127136" guid="f2de69b3-1043-403b-be1d-78560469f483">5731</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Green, A. K.</author><author>Saltz, L. B.</author></authors></contributors><auth-address>Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA</auth-address><titles><title>Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs</title><secondary-title>Journal of Clinical Oncology</secondary-title><alt-title>J Clin Oncol</alt-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><alt-periodical><full-title>J Clin Oncol</full-title></alt-periodical><pages>1381-1382</pages><volume>36</volume><number>13</number><dates><year>2018</year><pub-dates><date>May 1</date></pub-dates></dates><isbn>0732-183x</isbn><accession-num>WOS:000433528700019</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:000433528700019</url></related-urls></urls><electronic-resource-num>10.1200/Jco.2018.78.4397</electronic-resource-num><language>English</language></record></Cite></EndNote>(7). This does not include the cost of inpatient monitoring and toxicity management, which can add hundreds of thousand dollars. Insurance coverage for the treatment varies with many payers making coverage decisions on a case-by-case basis. Even when payers cover the cost of treatment, however, patients often are responsible for expenses such as travel, copays, etc. From a national health care perspective, CAR-T costs have been manageable because the eligible population for CAR-T remains small. If CAR-T demonstrates benefit across a broader range of malignancies, it might be used in millions, raising cost concerns for health systems ADDIN EN.CITE <EndNote><Cite><Author>Green</Author><Year>2018</Year><RecNum>5731</RecNum><DisplayText>(7)</DisplayText><record><rec-number>5731</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1577127136" guid="f2de69b3-1043-403b-be1d-78560469f483">5731</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Green, A. K.</author><author>Saltz, L. B.</author></authors></contributors><auth-address>Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA</auth-address><titles><title>Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs</title><secondary-title>Journal of Clinical Oncology</secondary-title><alt-title>J Clin Oncol</alt-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><alt-periodical><full-title>J Clin Oncol</full-title></alt-periodical><pages>1381-1382</pages><volume>36</volume><number>13</number><dates><year>2018</year><pub-dates><date>May 1</date></pub-dates></dates><isbn>0732-183x</isbn><accession-num>WOS:000433528700019</accession-num><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:000433528700019</url></related-urls></urls><electronic-resource-num>10.1200/Jco.2018.78.4397</electronic-resource-num><language>English</language></record></Cite></EndNote>(7). Prognostic Uncertainty: Although treatment carries quality of life, morbidity, and mortality risks, many patients face almost certain death without CAR-T. Also, it can be challenging to identify which patients will/will not have durable responses. Advance care planning is therefore nuanced given the prognostic uncertainty, and the unique nature of a binary outcome. This differs from our traditional understanding of disease trajectory for advanced malignancies. It is important to balance the hope for a good response, with the realization that good outcomes are not guaranteed and rapid trajectory to end-of-life is possible. References: ADDIN EN.REFLIST 1.Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31-46.2.Chong EA, Svoboda J, Nasta SD, et al. CD19‐directed car t cell therapy (CTL019) for relapsed/refractory diffuse large B‐cell and follicular lymphomas: four year outcomes. Hematol Oncol. 2019;37(suppl S2):137-138. doi: 10.1002/hon.96_2629.3.Van den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplantation. 2016;51(1):51-7.4.Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17.5.Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book. 2019;39:433-44.6.Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.7.Green AK, Saltz LB. Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. Journal of Clinical Oncology. 2018;36(13):1381-2.Authors’ Affiliations: Johns Hopkins Medicine, Baltimore, MD; Massachusetts General Hospital, Boston, MA.Conflicts of Interest: The authors declare that they have no conflict of interest. Version History: First electronically published in March 2020. Originally edited by Sean Marks MD.Fast Facts and Concepts are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual Fast Fact are solely responsible for that Fast Fact’s content. The full set of Fast Facts are available at Palliative Care Network of Wisconsin with contact information, and how to reference Fast Facts.Copyright: All Fast Facts and Concepts are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (). Fast Facts can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a Fast Fact, let us know!Disclaimer: Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download